We also observed subclonal copy gain of KRAS in all 8 samples, as well as subclonal copy loss of both ELOVL2 and IRF4 (Figure 1), all of which have been identified in tumours although the effect of these copy number losses in AML is unknown. This evidence concerns the gene KRAS and acute myeloid leukemia.